• 1
    Scandinavian Simvastatin Survival Group: Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 13831389
  • 2
    Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 13011307
  • 3
    Sacks FM, Pfeffer MA, Moyé LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 10011009
  • 4
    The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 13491357
  • 5
    Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. J Am Med Assoc 1988; 279: 16151622
  • 6
    Pearson TA, Laurora I, Chu H, Kafonek S: The Lipid Treatment Assessment Project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459467
  • 7
    National Institutes of Health, U.S. Dept. of Health and Human Services; 1993. NIH publication 93-3096. National Center for Health Statistics: National Health and Nutrition Examination Survey (III). Atlanta, Ga.: Centers for Disease Control and Prevention, 1994
  • 8
    Straka RJ, Taheri R, Cooper SL, Tan AWH, Smith JC: Assessment of hypercholesterolemia control in a managed care organization. Pharmacotherapy 2001; 21: 818827
  • 9
    Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 722
  • 10
    Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM: Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 110
  • 11
    Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN: REVERSAL Investigators: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. J Am Med Assoc 2004; 291: 10711080
  • 12
    Jones P, Kafonek S, Laurora I, Hunninghake D, for the CURVES Investigators: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81: 582587
  • 13
    Foley KA, Simpson RJ Jr, Crouse JR III, Weiss TW, Markson LE, Alexander CM: Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003; 92: 7981
  • 14
    Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I, von Bergmann K: Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002; 106: 19431948
  • 15
    Knapp HH, Schrott H, Ma P, Knopp R, Chin B, Gaziano JM, Donovan JM, Burke SK, Davidson MH: Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001; 110: 352360
  • 16
    Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, Suresh R, Sun S, Veltri EP, on behalf of the Ezetimibe Study Group: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40: 21252134
  • 17
    Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP, for the Ezetimibe Study Group: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia. A prospective, randomized, double-blind trial. Circulation 2003; 107: 24092415
  • 18
    Melani L, Mills R, Hassman D, Lipetz R, Lipka L, LeBeaut A, Suresh R, Mukhopadhyay P, Veltri E: Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Eur Heart J 2003; 24: 717728
  • 19
    Kerzner B, Corbelli J, Sharp S, Lipka LJ, Melani L, LeBeaut A, Suresh R, Mukhopadhyay P, Veltri EP: Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003; 91: 418424
  • 20
    Gagne C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, Cho M, Musliner TA, Gumbiner B, for the Ezetimibe Study Group: Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002; 90: 10841091
  • 21
    Goldberg AC, Capece R, Sapre A, Liu J, Mitchel Y: Efficacy of ezetimibe 10 mg/day coadministered with multiple doses of simvastatin in patients with primary hypercholesterolemia (abstr 1084-1174). J Am Coll Cardiol 2004; 42 (suppl A): 480A
  • 22
    Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J: Efficacy of ezetimibe coadministered with simvastatin vs. atorvastatin in patients with hypercholesterolemia (abstr 1084-1176). J Am Coll Cardiol 2004; 42 (suppl A): 480A
  • 23
    Proctor SD, Mamo JC: Retention of fluorescent-labeled chylomicron remnants within the intima of the arterial wall—evidence that plaque cholesterol may be derived from post-prandial lipoproteins. Eur J Clin Invest 1998; 28: 497503
  • 24
    Dane-Stewart CA, Watts GF, Barrett PH, Stuckey BG, Mamo JC, Martins IJ, Redgrave TG: Chylomicron remnant metabolism studied with a new breath test in postmenopausal women with and without type 2 diabetes mellitus. Clin Endocrinol 2003; 58: 415420
  • 25
    van Heek M, Compton DS, Davis HR: The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur J Pharmacol 2001; 415: 7984
  • 26
    Sudhop T, Gottwald BM, von Bergmann K: Serum plant sterols as a potential risk factor for coronary heart disease. Metabolism 2002; 51: 15191521
  • 27
    Assmann G, Cullen P, Erbey JR, Ramey DR, Kannenberg F, Schulte H: Elevation in plasma sitosterol concentration is associated with an increased risk for coronary events in the PROCAM study (abstr). Circulation 2003; 108: IV-730
  • 28
    Salen G, von Bergmann K, Lütjohann D, Kwiterovich P, Kane J, Patel SB, Musliner T, Stein P, Musser B: Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 2004; 109: 966971
  • 29
    Assmann G, Kannenberg F, Weng W, Erbey J, John A, Tribble D, Musliner T, Lipka LJ, Veltri EP: Effects of ezetimibe, simvastatin, and ezetimibe-simvastatin on non-cholesterol sterol (abstr 1008-1183). J Am Coll Cardiol 2004; 42 (suppl A): 445A
  • 30
    Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 15571565
  • 31
    Paul A, Ko KW, Li L, Yechoor V, McCrory MA, Szalai AJ, Chan L: C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004; 109: 647655
  • 32
    Sager PT, Melani L, Lipka L, Strony J, Yang B, Suresh R, Veltri E, for the Ezetimibe Study Group: Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003; 92: 14141418
  • 33
    Brookes L: Latest results with new lipid-lowering therapies. Available at: Accessed March 24, 2004
  • 34
    Study of Heart and Renal Protection (SHARP): Background information for International Coordinating Centre Candidates. Available at:∼jobs/sharpbg.htm. Accessed March 24, 2004